This technology is a pyridoxamine-based coating for transplantable heart valves that minimizes deterioration caused by calcification, oxidation, and protein deposition.
Bioprosthetic heart valves derived from bovine or porcine tissue are widely used in valve replacement surgery but are limited by structural valve degeneration over time. This degeneration is driven by tissue calcification, oxidative damage, and the accumulation of serum proteins and advanced glycation end products, which progressively compromise valve integrity. As a result, many patients require reoperation, which carry substantial surgical risk, particularly in elderly or high-risk populations. There is a need for strategies that delays valve degenerative, extend bioprosthetic valve lifespan, and improve long-term patients’ outcomes.
This technology is a set of pyridoxamine-based formulations for the pretreatment of bioprosthetic heart valves. The chemical addition of photoreactive benzophenone to pyridoxamine facilitates the covalent attachment of pyridoxamine to the valve. This pyridoxamine coating mitigates calcification, oxidation, and deposition of proteins on the valve leaflets. As such, these solutions can be used to prevent the structural degradation of transplanted heart valves and enhance their value as a treatment for heart valve disease.
Patent Pending
IR CU24189
Licensing Contact: Jerry Kokoshka
